Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS +1.64%89 Days Sales Outstanding is 51.17 as of Dec. 2025, which is 2% above its 10-year median of 50.04. GuruFocus rates ASX:VLS with a GF Score™ of 89/100 and a GF Value™ of A$2.50 (Fairly Valued). The stock has 1 warning sign investors should review. Among 950 Drug Manufacturers companies, Vita Life Sciences ranks better than 73.89% on this metric.
The historical rank and industry rank for Vita Life Sciences's Days Sales Outstanding or its related term are showing as below:
ASX:VLS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.52 Med: 50.04 Max: 57.44
Current: 50.43
During the past 13 years, Vita Life Sciences's highest Days Sales Outstanding was 57.44. The lowest was 42.52. And the median was 50.04.
ASX:VLS's Days Sales Outstanding is ranked better than 73.89% of 950
companies
in the Drug Manufacturers industry
Industry Median: 72.065
vs ASX:VLS: 50.43
Vita Life Sciences's Days Sales Outstanding
declined
from Dec. 2024 (55.21) to Dec. 2025 (51.17).
Vita Life Sciences (ASX:VLS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Vita Life Sciences Days Sales Outstanding Related Terms
Vita Life Sciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Days Sales Outstanding falls into.
Vita Life Sciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Days Sales Outstanding of 51.17 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vita Life Sciences and its competitors. This is near median its historical median of 50.04. Over the past decade, Vita Life Sciences' Days Sales Outstanding has ranged from 42.52 to 57.44. According to the industry distribution chart, Vita Life Sciences ranks #248 out of 950 companies in the Drug Manufacturers industry, placing it in the top 26.1%.
Is Vita Life Sciences' Days Sales Outstanding too high?
Vita Life Sciences' current Days Sales Outstanding of 51.17 is near median its 10-year median of 50.04. Over the past 10 years, this metric has ranged from a low of 42.52 to a high of 57.44. The Drug Manufacturers industry median Days Sales Outstanding is 72.07. Vita Life Sciences' value of 51.17 is 29% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #248 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #248 out of 950 companies for Days Sales Outstanding. This puts Vita Life Sciences in the upper half of its industry. The industry median Days Sales Outstanding is 72.07. Vita Life Sciences' value of 51.17 is 29% below this benchmark. Historically, Vita Life Sciences' own Days Sales Outstanding has ranged from 42.52 to 57.44 over the past decade. While the company's 10-year median is 50.04 vs. the industry median of 72.07, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Days Sales Outstanding of 51.17 is 29% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Days Sales Outstanding is 51.17, which is near median its own 10-year median of 50.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.50, compared to a current price of A$2.48 — trading 0.8% below its estimated fair value. The current Days Sales Outstanding is 51.17, which is near median its 10-year median of 50.04 and 29% below the Drug Manufacturers industry median of 72.07. Vita Life Sciences' overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Days Sales Outstanding is 51.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.48 is trading 0.8% below its estimated GF Value™ of A$2.50.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Days Sales Outstanding: 51.17 (near median its 10-year median of 50.04)
GF Value™: A$2.50 vs. price of A$2.48 (0.8% below fair value)
Industry Position: 29% below the Drug Manufacturers median (#248 of 950)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
89GF Score
Get the complete analysis for ASX:VLS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
